Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006124 · ClinicalTrials.gov registry record · Phase 2
Celecoxib in Treating Patients With Bladder Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT00006124: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00006124 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 152 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006124, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
This randomized phase IIb/III trial is studying celecoxib to see how well it works in preventing disease recurrence in patients who have bladder cancer. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of bladder cancer
Interventions
- DRUG placebo
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2000-06 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006124
The ClinicalTrials.gov registry entry for NCT00006124 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00006124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006124 about?
NCT00006124 is a clinical study titled "Celecoxib in Treating Patients With Bladder Cancer". This randomized phase IIb/III trial is studying celecoxib to see how well it works in preventing disease recurrence in patients who have bladder cancer. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effec...
What is the current status of trial NCT00006124?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2000-06. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00006124?
The interventions under investigation include: placebo (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00006124?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.